In the process of characterizing new formulations of filgrastim being developed (Sandoz filgrastim development sample, formulation B), two new variants were observed.
The data from Bristol and Birmingham were used to develop the prognostic models (development sample) and the models were validated on the data from Wolverhampton (validation sample).
We used a cohort of 1642 consecutive surgical patients (development sample) that were treated in the UMC Utrecht to develop prediction models.
In the equation development sample, multiple linear regression analysis was used to develop equations for predicting FFM as measured using isotope dilution, from resistance measured by BIA.
First, the score was developed just at a single site in a university hospital setting, and the development sample was relatively small.
A total of 21,133 persons included in the PROMIS development sample: 52% female; 82% White, 9% Black, 9% Hispanic; median age of 50 years.
They are: definition of research goals, frame construction, choice of data collection mode, questionnaire development, sample design, data collection, and data processing.
As might also be expected, the ROCmax method did not produce as large a C-statistic in the validation sample (NIS) as it had in the development sample (NTDB).
The model development sample was patients who were enrolled into a clinical trial.
Prediction in the validation sample was generally less powerful than in the development sample.
The development sample included 200 patients with chronic conditions from 6 family medicine clinics.
